Form 4: Catalyst Pharmaceuticals Executive Reports Stock Transaction
Insider Transaction (Form 4)
Preethi Sundaram, Chief Strategy Officer of Catalyst Pharmaceuticals, Inc., reported multiple transactions in common stock on July 15, 2026.
Summary
- Disposition to the issuer: disposed of 54,804 Common Stock, par value $0.001 per share at $31.50 ($1,726,326) on July 15, 2026 (Direct).
- Disposition to the issuer: disposed of 225,000 Options to purchase common stock on July 15, 2026 (Direct).
- Disposition to the issuer: disposed of 67,500 Options to purchase common stock on July 15, 2026 (Direct).
- Disposition to the issuer: disposed of 68,000 Options to purchase common stock on July 15, 2026 (Direct).
- Disposition to the issuer: disposed of 143,193 Options to purchase common stock on July 15, 2026 (Direct).
- Disposition to the issuer: disposed of 137,553 Options to purchase common stock on July 15, 2026 (Direct).
- Disposition to the issuer: disposed of 106,873 Options to purchase common stock on July 15, 2026 (Direct).
- Disposition to the issuer: disposed of 6,855 Restricted Stock Units on July 15, 2026 (Direct).
- Disposition to the issuer: disposed of 11,206 Restricted Stock Units on July 15, 2026 (Direct).
- Disposition to the issuer: disposed of 32,257 Restricted Stock Units on July 15, 2026 (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Preethi Sundaram — Officer (Chief Strategy Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-15 | Disposition to the issuer | Common Stock, par value $0.001 per share | 54,804 | $32 | $1.7M | 0 |
| 2026-07-15 | Disposition to the issuer | Options to purchase common stock | 225,000 | — | — | 0 |
| 2026-07-15 | Disposition to the issuer | Options to purchase common stock | 67,500 | — | — | 0 |
| 2026-07-15 | Disposition to the issuer | Options to purchase common stock | 68,000 | — | — | 0 |
| 2026-07-15 | Disposition to the issuer | Options to purchase common stock | 143,193 | — | — | 0 |
| 2026-07-15 | Disposition to the issuer | Options to purchase common stock | 137,553 | — | — | 0 |
| 2026-07-15 | Disposition to the issuer | Options to purchase common stock | 106,873 | — | — | 0 |
| 2026-07-15 | Disposition to the issuer | Restricted Stock Units | 6,855 | — | — | 0 |
| 2026-07-15 | Disposition to the issuer | Restricted Stock Units | 11,206 | — | — | 0 |
| 2026-07-15 | Disposition to the issuer | Restricted Stock Units | 32,257 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-15 | Disposition to the issuer (54,804 shares) |
| 2026-07-15 | Disposition to the issuer (225,000 shares) |
| 2026-07-15 | Disposition to the issuer (67,500 shares) |
| 2026-07-15 | Disposition to the issuer (68,000 shares) |
| 2026-07-15 | Disposition to the issuer (143,193 shares) |
| 2026-07-15 | Disposition to the issuer (137,553 shares) |
| 2026-07-15 | Disposition to the issuer (106,873 shares) |
| 2026-07-15 | Disposition to the issuer (6,855 shares) |
| 2026-07-15 | Disposition to the issuer (11,206 shares) |
| 2026-07-15 | Disposition to the issuer (32,257 shares) |
Keywords
insider transaction, Form 4, CPRX, CATALYST PHARMACEUTICALS, INC., neutral, Preethi Sundaram
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.